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RADIOBIOLOGICAL BASIS OF LOW-DOSE IRRADIATION IN PREVENTION
AND THERAPY OF CANCER
Myron Pollycove  North Bethesda, MD
 Antimutagenic DNA damage-control is the central component of the homeostatic con-
trol essential for survival. Over eons of time, this complex DNA damage-control system
evolved to control the vast number of DNA alterations produced by reactive oxygen
species (ROS), generated principally by leakage of free radicals from mitochondrial
metabolism of oxygen. Aging, mortality and cancer mortality are generally accepted to be
associated with stem cell accumulation of permanent alterations of DNA, i.e., the accu-
mulation of mutations. In a young adult, living in a low LET background of 0.1 cGy/y, the
antimutagenic system of prevention, repair and removal of DNA alterations reduces about
one million DNA alterations/cell/d to about one mutation/cell/d. DNA alterations from
background radiation produce about one additional mutation per 10 million cells/d. As
mutations accumulate and gradually degrade the antimutagenic system, aging progresses
at an increasing rate, mortality increases correspondingly, and cancer increases at about
the fourth power of age. During the past three decades, genomic, cellular, animal and
human data have shown that low-dose ionizing radiation, including acute doses up to 30
cGy, stimulates each component of the homeostatic antimutagenic control system of
antioxidant prevention, enzymatic repair, and immunologic and apoptotic removal of
DNA alterations. On the other hand, high-dose ionizing radiation suppresses each of these
antimutagenic protective components. Populations living in high background radiation
areas and nuclear workers with increased radiation exposure show lower mortality and
decreased cancer mortality than the corresponding populations living in low background
radiation areas and nuclear workers without increased radiation exposure. Both studies of
cancer in animals and clinical trials of patients with cancer also show, with high statistical
confidence, the beneficial effects of low-dose radiation. 
I. INTRODUCTION
Four decades of genomic, cellular, animal and human data have
shown that low-dose ionizing radiation stimulates positive genomic and
cellular responses associated with effective cancer prevention and thera-
py and increases the life span of mammals and humans.[1-8] Nevertheless,
this data is questioned because it seems to contradict the unquestioned
linear relation between ionizing radiation dose and damage to DNA with-
out providing a clear mechanistic explanation of how low-dose radiation
could produce such beneficial effects. Acknowledgment of the validity of
this contradictory data would destroy the basis of a very expensive system
of regulation and remediation.
A quantitative understanding of the antimutagenic DNA damage-con-
trol system essential for survival was recently developed[9] and is illustrated
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in Figure 1. This complex system evolved in aerobic organisms over eons
of time in order to control an enormous, relentless burden of DNA alter-
ations produced by reactive oxygen species (ROS), generated principally
by free radicals leaked from mitochondrial oxygen metabolism. This
antimutagenic system also operates against the DNA damage generated by
ionizing radiation ROS and by chemicals. The enhanced response of the
antimutagenic system to low-dose radiation provides a clear mechanistic
explanation of the beneficial effects seen in cells, mammals and humans.
II. THE ANTIMUTAGENIC DNA DAMAGE-CONTROL SYSTEM
The immune system is an essential component of antimutagenic con-
trol of cumulative DNA damage and metabolic damage generated by a
relentless burden of DNA alterations produced by ROS leaked from mito-
chondria.[10] In addition to removal of persistent DNA alterations by the
immune system and cellular programmed self-destruction (apoptosis),
the human antimutagenic system includes antioxidant prevention and
enzymatic repair of DNA damage. This complex biosystem of prevention,
repair and removal sequentially reduces DNA damage from about one
million DNA alterations/cell/day to about one “mutation”/cell/day
(Figure 1). In contrast, low LET background radiation of 1 mGy/year
produces 1 DNA alteration/500 cells/day. Double-strand breaks/cell/day
generated by oxygen metabolism is 1000 times greater than the double-
strand breaks produced by this background radiation. The UNSCEAR
1994 Report[11] and recent studies[12, 13] furnish extensive documentation
FIGURE 1. The antimutagenic DNA damage-control biosystem. Estimates are based on data in the
literature.9
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of low-dose stimulation of many cellular functions including: antioxidant
prevention (Figure 2)[14], enzymatic repair (Figures 3 and 4)[15, 16], and
immunologic and apoptotic removal (Figure 5)[17] of DNA damage. This
stimulation of each of these antimutagenic responses by low-dose radia-
tion, in contrast to their suppression by high-dose radiation, predictably
precludes a linear dose-response relation of radiation and health
effects.[18] Enhanced prevention of gene mutations by increased low-dose
radiation (Figure 6) is associated with decreased mortality and decreased
cancer mortality observed in human populations exposed to low-dose
FIGURE 2. Antioxidant SOD and lipid peroxide response to age and radiation of rat brain cortex14
FIGURE 3. Low dose induced DNA repair15
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radiation.[19-21] Stimulation of the immune system by low-dose radiation
prevents and removes cancer metastases in rodents and humans.
III. IMMUNE SYSTEM RESPONSE TO RADIATION
Low-dose total body irradiation (TBI) and chronic TBI (LDR) stimu-
late immune system prevention and removal of cancer metastases. This
has been observed in mice for about 40 years[16, 22, 23] and more recently
in rats[24] and humans.[3-6, 8, 25-29]
The maximal immune response of mouse spleen T lymphocytes to
sheep red blood cells, both in vitro and in vivo, occurs after a single dose
of 0.25 Gy or 25 r (Figure 7).[23] The maximal in vitro response is 180%
with suppression to 50% of control after 100 r. The maximal in vivo
response is 145%, but more than 260 r is needed for suppression to 50%
of control.
FIGURE 4. Mean chromosomal aberrations per cell in lymphocytes before and after exposure to 150
r. Lymphocytes were obtained from Ramsar residents in a high background γ radiation area of about
10 mGy/y and residents in a normal background γ radiation area of about 1 mGy/y.16
FIGURE 5. Eight month old, mammary tumor-susceptible, female C3H/He mice were first adjusted
in a stepwise manner to chronically restricted diet (calorically 70% of ad libitum diet) over a period
of 3 weeks. The mice were maintained on CRD until completion of the study. After their diet was
adjusted, the mice were exposed to TBI (0.04 Gy, 3 alternating days/week, 4 weeks) and were
observed for 35 weeks. Tumor regression of the CRD + TBI group was very rapid and large numbers
of CD8+ T cells were found infiltrating the regressing tumors, which were not seen in mice of the
untreated control, LDR and CRD groups.17
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TBI given with subimmunogenic tumor antigen induces tumor
immunization. Subcutaneous inoculation of sham irradiated controls
with 100 non-viable tumor cells does not suppress growth of 10,000 viable
tumor cells inoculated subcutaneously 21 days later. Strikingly, 15 r of TBI
given simultaneously with inoculation of 100 non-viable tumor cells does
induce marked suppression of tumor cell growth, exceeding that induced
by 100,000 non-viable tumor cells without TBI (Figure 8).[22]
FIGURE 6. The antimutagenic DNA damage-control biosystem response to high background radia-
tion = 120%. Estimates based on data in the literature.9
FIGURE 7. Immune system response to radiation. Mouse splenic cells primed with antigenic sheep
red blood cells.23
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TBI stimulates immune suppression of tumor metastases to the lung
(Figure 9).[8] Lung colonies, counted 20 days after TBI given 12 days after
tumor cell transplantation into the axilla of mice, were decreased by TBI
doses less than 50 r; 15 r induced the maximal decrease of 60%. However,
high doses in the 50-100 r range suppressed the immune system, with
increased metastases to lung.
Chronic TBI (LDR) stimulates immune response of spleen T lympho-
cyte proliferation in mice (Figure 10).[23] Mice irradiated 5 days/week for
4 weeks with LDR courses of 10 r (0.5 r/d), 20 r (1.0 r/d) and 80 r (4.0 r/d)
showed lymphocyte responses of 115%, 140%, and 160%, respectively, rel-
ative to 100% proliferation in the unirradiated control group.
FIGURE 8. Effect of 0.15 Gy upon response of A/J mice to subimmuno-genic and immunogenic
numbers of non-viable mitomycin-treated fibrosarcoma (SaI) tumor cells. Groups of 60 mice were
exposed to whole-body irradiation or sham-irradiated and inoculated subcutaneously with the indi-
cated numbers of mitomycin-treated tumor cells. Twenty-one days later, all animals received 104
untreated SaI cells and were followed for tumor size. A control group did not receive mitomycin-
treated cells.22
FIGURE 9. TBI given 12 days after tumor cell transplantation into axilla. Lung colonies counted 20
days after TBI. Low dose TBI ineffective with spleen blocked. Low dose splenic irradiation, half-body
irradiation (HBI) and TBI equally effective.8
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LDR with a calorically-restricted diet, of 70% ad libitum diet calo-
ries, prevents and removes spontaneous breast cancer tumors in mice
(Figure 5).[17] Eight-month-old breast tumor susceptible female mice,
after 3-week adjustment to CRD, were exposed to a 48 r, 4-week course
of LDR (4 r 3d/week) and then observed for 35 weeks. While 73% of
the ad libitum diet mice and 27% of the CRD mice developed breast
cancer, only 16% of CRD + LDR mice developed breast cancer. Most
impressive was the very rapid 80% tumor regression of CRD + LDR mice
compared to the 20% and 4% regression in CRD and control mice,
respectively. Large numbers of “killer” cytotoxic CD8+ T lymphocytes
were observed infiltrating regressing tumors of CRD+LDR mice, but not
in the control and CRD mice. Half-body LDR of women given 5-30 r by
25 to 150 fluoroscopic lung examinations similarly decreased breast
FIGURE 10. Dose-response analysis of splenic T cell proliferative response 3-5 days after the last radi-
ation exposure of immunologically normal, long-lived C57B1/6J+/+ mice. Results are expressed as
the mean percent increase in 3H-thymidine uptake relative to 0 Gy control group as 100%. The ver-
tical bars = 1 SEM.23
FIGURE 11. Reduced breast cancer mortality of tuberculosis patients who received LDI during
fluoroscopy24, 25
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cancer mortality. Breast cancer mortality of those receiving doses between
10-20 r was reduced to 66% of controls without LDR (Figure 11).[24,25]
Metastasis is also suppressed by TBI of tumor-bearing rats (Figure 12).[26]
TBI or irradiation localized to tumor implanted into the leg or control
sham-irradiation were given 14 days after tumor implantation. The number
of visible metastases in the lung and the incidence of metastases in medi-
astinal and axillary lymph nodes were obtained 50 days after implantation.
The number of tumor infiltrating lymphocytes/microscopic field was
observed 21 days after implantation. Metastases to the lung, mediastinum
and axillary lymph nodes in TBI rats were reduced by more than 70% of
that in control and locally irradiated rats. Tumor infiltration by lympho-
cytes in TBI rats was more than 900% of that in control and locally irradi-
ated rats. Cytotoxic CD8+ T lymphocytes in the spleen of TBI rats were
increased to 176% of those in control and locally irradiated rats.
FIGURE 12. The number and incidence of metastases in lung and lymph nodes of mediastinum and
axilla 50 days after intramuscular (leg) tumor implantation in rats, and the number of tumor infil-
trating lymphocytes 21 days after implantation. Total body or localized tumor irradiation with 0.2 Gy
was given 14 days after implantation of 5 x 105 allogenic hepatoma cells.26
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IV. HUMAN LOW DOSE RADIATION (LDR) CANCER IMMUNOTHERAPY
Two Harvard University clinical trials of LDR therapy in patients
with non-Hodgkin’s lymphoma were published in 1976[27] and in 1979
(Figure 13).[28] The protocols were very similar. The Chaffey, et al. 1976
trial used a 150 r LDR course with TBI doses of 15 r 2x/week for 5
weeks. The Choi, et al. 1979 trial also used a 150 r LDR course with TBI
doses of either 15 r 2x/week or 10 r 3x/week for 5 weeks. In both stud-
ies transient low platelets requiring interruption of scheduled therapy
occurred in 35-40% of patients, irrespective of 10 r or 15 r dose sched-
ule. Both chemotherapy and LDR patients had previously received
chemotherapy and localized tumor high-dose radiation. Histologic
tumor grades of LDR and chemotherapy patients were similar. COP
chemotherapy used in the 1976 trial was replaced by the more effective
CHOP chemotherapy still in current use. Both trials furnish 4-year sur-
vival data. Four-year survival in the 1976 study of 25 LDR patients is 70%
compared with 40% survival of 24 matched patients treated with
COP.[26] The 1979 trial shows a similar 74% survival of 39 LDR patients
compared with improved 52% survival of 225 patients treated with
CHOP (Figure 13).[28]
Sakamoto, et al., Tohoku University, Sendai, Japan, published a 1997
review of their experimental studies in mice and a clinical trial of LDR.
In mice, 15 r TBI induced maximal suppression of tumor metastasis
(Figure 9).[8] TBI given 6-12 hours before localized high-dose tumor
therapy increases the effectiveness of tumor therapy. TBI, upper half
body irradiation (HBI), and localized irradiation of the spleen were
equally effective in stimulating the immune system of mice.
FIGURE 13. Comparison of TBI with CHOP chemotherapy. CHOP remains the best available
chemotherapy treatment for patients with advanced-stage intermediate-grade or high-grade non-
Hodgkin’s lymphoma.28
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The protocol used by Sakamoto, et al. in their clinical trial of LDR
therapy of patients with non-Hodgkin’s lymphoma is similar to that used
by Choi, et al. Both used a 150 r LDR course with equally effective TBI
doses of either 15 r 2x/week or 10 r 3x/week for 5 weeks in patients with
previous CHOP chemotherapy and localized high-dose tumor irradia-
tion. Choi, et al. used TBI, while Sakamoto, et al. used TBI or HBI
(Figure 14) with equal effectiveness without interruption of scheduled
therapy by low platelets. 
Sakamoto, et al. report 9-year survival of 23 LDR patients and 94
CHOP chemotherapy patients with similar histologic tumor grades,
approximately 75% of each group having intermediate or high grade
lymphoma (Figure 15).[8] Tumors outside the HBI field regressed com-
pletely in response to LDR (Figure 16).[29] Nine-year survival of patients
FIGURE 14. Treatment of patients with non-Hodgkin’s lymphoma with half (HBI) or total (TBI)
body irradiation. Adapted from Sakamoto et al8
FIGURE 15. Utility of low-dose irradiation of HBI or TBI for patients with non-Hodgkin’s lymphoma.
Patients in both groups received chemothera-py and localized tumor high-dose radiation.8
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treated with LDR is 84%, unchanged from their 31/2-year survival. Survival
of these LDR patients at 12 years remains 84% (personal communica-
tion). In comparison, the 9-year survival of CHOP chemotherapy patients
is 50% (Figure 15).[8]
Comparison of 4-year survival in the Harvard and Tohoku LDR vs
CHOP trials are consistent in both showing about a 20% better survival
of LDR patients compared with CHOP patients. In the Japanese trial,
however, moderate decreases of platelets did not require schedule inter-
ruption, and the 4-year survival of both LDR and CHOP patients was
increased about 10% above those of the United States trial. This may be
related to the well-established benefits of lower caloric intake and more
exercise in the Japanese population. Though racial differences may be a
factor, this has not been demonstrated in Japanese living in the United
States. As shown by Makinodan (Figure 5)[17], LDR therapy is more effec-
tive when administered to mice with optimal caloric intake and better ini-
tial immune system activity.
V. NEED FOR CLINICAL TRIALS OF LDR IMMUNOTHERAPY OF BREAST,
PROSTATE AND COLORECTAL CANCER
Despite many hundreds of clinical trials of chemotherapy during the
past 40 years, breast cancer mortality has not decreased significantly while
prostate cancer mortality has risen steadily; colon and rectum cancer
mortality also remains high.[30] Chemotherapy is not winning the war
against cancer. In contrast, during this same period, research in mice,
and more recently in rats and humans, LDR was shown with high statisti-
cal confidence to be very effective in preventing and treating cancer.
Human clinical trials have shown this immunotherapy to be much more
effective in treating intermediate and high-grade stages of non-Hodgkin’s
lymphoma. Intensive further research during clinical trials is needed to
optimize course protocols of LDR immunotherapy and, when indicated,
FIGURE 16. CT scans of upper nasal cavity before and after HBI therapy. Though entirely outside
the HBI field, the nasal tumor completely disappeared.29
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the optimal interval between courses of LDR immunotherapy. LDR, in
contrast to chemotherapy, stimulates rather than depresses all compo-
nents of the antimutagenic biosystem and is asymptomatic without signif-
icant side effects. Published results of LDR immunotherapy justify cur-
rent initiation of clinical trials in patients with breast, prostate and col-
orectal cancer.
VI. CONCLUSION
Recent research has led to recognition of the importance of the
immune system in controlling cancer as well as infectious disease. LDR
cancer immunotherapy has been shown to be effective in rodents and
humans. Optimal protocols need to be developed by determining the
mechanisms, magnitude and duration of immune response, and the opti-
mal body localization of LDR needed to minimize marrow irradiation
while maintaining maximal immune stimulation. Published results justify
current support of well-designed clinical trials of LDR therapy in patients
with breast, prostate, colorectal, ovarian cancer, and lymphomas. Clinical
trials are also indicated to determine the effectiveness of LDR immune
stimulation in patients with early HIV and other infectious diseases, and
of LDR potentiation of vaccines to prevent HIV and other infectious dis-
eases. LDR of patients is asymptomatic with minimal side effects, a ration-
al and very promising way of using our antimutagenic system to control
cancer and infection. 
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